Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06225336




Registration number
NCT06225336
Ethics application status
Date submitted
17/01/2024
Date registered
25/01/2024
Date last updated
29/01/2024

Titles & IDs
Public title
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)
Scientific title
A Phase 1/2, Single-Center, Open-Label, Single-Arm Safety, Tolerability, and Efficacy Study of an Auricle and Wedge Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
Secondary ID [1] 0 0
AUR-201-02
Universal Trial Number (UTN)
Trial acronym
AUR-201
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Microtia 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Ear 0 0 0 0
Other ear disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - AUR-201

Experimental: AUR-201 - AUR-201


Other interventions: AUR-201
Auricle and wedge subcutaneous implant consisting of 3-D printed autologous auricular sourced chondrocytes in a biopolymer matrix.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of Treatment-Emergent Adverse Events
Timepoint [1] 0 0
24 weeks
Primary outcome [2] 0 0
Appearance/Efficacy of the AUR-201 Implant
Timepoint [2] 0 0
24 weeks

Eligibility
Key inclusion criteria
1. Child between 8 and 17 years of age (inclusive) at the time the guardian signs the ICF or adult between 18 and 29 years of age (inclusive) at the time of signing the ICF. Note, the implantations of AUR-201 will initially be staggered based on age and completion of specified DSMB evaluations (see Methodology section);
2. Diagnosed with Grade II, III, or IV congenital unilateral microtia requiring complete auricular reconstruction;
3. Naïve to microtia surgery or have had prior failed microtia surgery not involving the TPF flap;
4. Able and willing to adhere to the post-operative wound care instructions (including, but not limited to, wearing protective devices specified by the PI) and the protocol-specified follow-up schedule;
5. Willing to refrain from non-contact sports and contact sports (e.g., football, soccer, rugby, boxing, karate) for 6 and 12 weeks, respectively, following the first implantation surgery, or longer if deemed necessary for healing by the PI. If the PI opts to implant the AUR-201 wedge at a separate subcutaneous location on Day 0 and then 12 weeks later, implants the wedge in the final location, these periods of refraining from non-contact and contact sports will also apply to the second implantation surgery;
6. PI deems the subject an appropriate candidate for the planned AUR-201 biopsy and implantation procedures (i.e., either the TPF flap technique or the pocket technique) and that the subject meets the following criteria:

1. Healthy auricular cartilage donor site (e.g., conchal bowl site) on contralateral (non-microtic) ear available for biopsy;
2. Healthy skin tissue at site of planned microtia repair;
7. Healthy (other than for microtia) as determined by the PI based on medical history, physical examinations, body weight, vital signs, 12-lead electrocardiogram (ECG), and safety laboratory tests at screening/pre-biopsy baseline;
8. Negative test results for human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum (i.e., syphilis), and West Nile virus 1 (WNV-1) within seven days prior to the biopsy for harvesting auricular cartilage from the contralateral ear;
9. Able to understand the English language;
10. Subject or guardian able to understand the ICF and give informed consent/assent;
11. Subject or guardian signed the ICFs for both this study (Protocol No. AUR-201-02) and the long-term follow-up (LTFU) study (Protocol No. AUR-201-04);
12. Women of childbearing potential (WCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test at the pre-biopsy baseline visit;
13. WCBP must agree to abstain from sex or use an adequate method of contraception* from the time of informed consent through the last study visit at 96 weeks post-implantation;
14. Males must abstain from sex with WCBP or use an adequate method of contraception* from the time of informed consent through the last study visit at 96 weeks post-implantation;

* Adequate contraceptive methods include those with a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as some double barrier methods (condom with spermicide) in conjunction with use by the partner of an intrauterine device, diaphragm with spermicide, oral contraceptives, birth control patch or vaginal ring, or injectable or implanted contraceptives. Abstinence is acceptable only as true abstinence: when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

A woman that is postmenopausal (=2 years since last menstrual period) or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy) is not considered a WCBP.
Minimum age
8 Years
Maximum age
29 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Any comorbidities likely to affect healing or the ability to adhere to the protocol, including:

1. Burns, trauma, problematic wound healing, or scarring skin malformations at the planned site of microtia repair or the planned site of biopsy collection for auricular cartilage;
2. Squamous cell carcinoma, basal cell carcinoma, or melanoma at the planned site of microtia repair or the planned site of biopsy collection for auricular cartilage;
3. Uncontrolled diabetes or hypertension;
4. History of diabetes requiring amputation or dialysis;
5. Serious autoimmune disorder, or ongoing immunocompromised state;
6. Current or recent history (within four weeks prior to initial screening visit) of a clinically significant bacterial, fungal, or mycobacterial infection;
7. Current clinically significant viral infection;
8. History of human transmissible spongiform encephalopathies (TSEs), including Creutzfeldt-Jakob disease;
9. History of Zika virus infection;
10. Completed treatment of syphilis within 12 months prior to screening;
11. Uncontrolled acne vulgaris in the area of the planned AUR-201 implantation site;
12. History of organ transplant;
13. Major cardiac, pulmonary, renal, hepatic, metabolic, neurologic, or urologic disorders;
2. Predisposition or history of keloid or hypertrophic scar development;
3. Lifestyle activities likely to affect healing or ability to adhere to the protocol (e.g., active contact sports and protective gear that interferes with wearing post-operative silicone molds and plastic ear cup);
4. Diagnosed with any of the following syndromes or conditions:

1. Treacher-Collins syndrome;
2. Nager syndrome;
3. Goldenhar syndrome or hemifacial microsomia plus an occlusal cant of 20 degrees or greater;
4. Absence of vertical ramus [as diagnosed on physical exam or computed tomography (CT)];
5. Absence of zygoma (as diagnosed on physical exam or CT);
6. Significant orbital asymmetry or micro-ophthalmia (as diagnosed on physical exam or CT);
7. History of major congenital disorder that could impact wound healing or cell expansion from the biopsy sample;
5. Inadequate renal function as indicated by serum creatinine >1.5 x the upper limit of normal (ULN) and either a >50% decrement of blood flow or anatomic abnormalities on renal scan;
6. Any condition which, in the opinion of the PI, places the subject at unacceptable risk if he/she were to participate in the study;
7. Treatment with an immunosuppressant within 6 months prior to screening;
8. Treatment with a chemotherapeutic within 12 months prior to screening;
9. Treatment with isotretinoin within 12 months prior to screening;
10. Treatment with oral steroids within 1 month prior to screening;
11. Current tobacco or illicit drug use;
12. Participation in another interventional (non-observational) clinical study (other than as a documented placebo subject with no interventions at the planned site of biopsy or implantation) within 6 months prior to screening;
13. Additional planned surgical procedures, including piercings, at the microtia or biopsy sites (i.e., beyond the AUR-201 biopsy and implantation procedures with skin grafts) during the subject's planned participation in this study;
14. Pregnant or breastfeeding (or planning to become pregnant or breastfeed during the study);
15. Presence of an implanted hearing enhancement device if it will interfere with the surgical technique (TPF flap or pocket) planned for AUR-201 implantation;
16. Known hypersensitivity to the biopolymer components used in the manufacture of AUR 201, including gellan gum and sodium alginate;
17. Known hypersensitivity to the components in the AUR-201 transport medium, including Dulbecco's Modified Eagle's Medium (DMEM), L-alanyl-L-glutamine, and 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES);
18. Known hypersensitivity to amide-containing anesthetics;
19. Known hypersensitivity to povidone iodine.

Study design
Purpose of the study
Treatment
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/11/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/05/2025
Actual
Sample size
Target
10
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment postcode(s) [1] 0 0
2050 - Camperdown

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Auregen Biotherapeutics, SA
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Joseph Dusseldorp, MD
Address 0 0
Chris O'Brien Lifehouse
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06225336